Skip to main content
Top
Published in: Supportive Care in Cancer 1/2010

01-01-2010 | Original Article

Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study

Authors: Rajesh V. Lalla, Carol C. Pilbeam, Stephen J. Walsh, Stephen T. Sonis, Dorothy M. K. Keefe, Douglas E. Peterson

Published in: Supportive Care in Cancer | Issue 1/2010

Login to get access

Abstract

Goals

Oral mucositis can be a significant and dose-limiting complication of high-dose cancer therapy. Mucositis is a particularly severe problem in patients receiving myeloablative chemotherapy prior to bone marrow or hematopoetic stem cell transplant (HSCT). The cyclooxygenase (COX) pathway mediates tissue injury and pain through upregulation of pro-inflammatory prostaglandins, including prostaglandin E2 (PGE2) and prostacyclin (PGI2). The objective of this small (n = 3) pilot study was to examine the role of the COX pathway in causing mucosal injury and pain in chemotherapy-induced oral mucositis.

Materials and methods

We collected blood, saliva, and oral mucosal biopsy specimens from three autologous HSCT patients at the following time-points before and after administration of conditioning chemotherapy: Day −10, +10, +28, and +100, where day 0 is day of transplant. RNA extracted from full-thickness tissue samples was measured by RT-PCR for the following: COX-1, COX-2, microsomal prostaglandin E synthase (mPGES), IL-1β, and TNF-α. Blood and saliva samples were measured by ELISA for PGE2 and PGI2, which are markers of COX activity. Severity of oral mucositis was determined using the Oral Mucositis Index. Severity of pain due to oral mucositis was measured using a Visual Analog Scale. Relationships between the different variables were examined using Spearman rank correlation coefficients.

Main results

Mean mucositis and pain scores increased significantly after administration of chemotherapy and then gradually declined. The correlation between changes in mucositis and pain scores was strong and statistically significant. The following additional correlations were statistically significant: between tissue COX-1 and pain; between tissue mPGES and pain; between salivary PGE1 and pain; between salivary PGI2 and pain. Other relationships were not statistically significant.

Conclusions

Our finding of significant associations of pain scores with tissue COX-1 and mPGES, as well as salivary prostaglandins, is suggestive of a role for the cyclooxygenase pathway in mucositis, possibly via upregulation of pro-inflammatory prostaglandins. However, our small sample size may have contributed to the lack of significant associations between COX-2 and other inflammatory mediators with mucosal injury and pain. Thus, additional studies with larger numbers of subjects are warranted to confirm the involvement of the cyclooxygenase pathway in chemotherapy-induced mucositis.
Literature
2.
go back to reference Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33–39PubMed Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33–39PubMed
3.
go back to reference Cheng KK (2007) Oral mucositis and quality of life of Hong Kong Chinese patients with cancer therapy. Eur J Oncol Nurs 11:36–42CrossRefPubMed Cheng KK (2007) Oral mucositis and quality of life of Hong Kong Chinese patients with cancer therapy. Eur J Oncol Nurs 11:36–42CrossRefPubMed
4.
go back to reference Choi SH, Langenbach R, Bosetti F (2008) Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. Faseb J 22:1491–1501CrossRefPubMed Choi SH, Langenbach R, Bosetti F (2008) Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. Faseb J 22:1491–1501CrossRefPubMed
5.
go back to reference Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA (1998) Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241:222–229CrossRefPubMed Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA (1998) Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241:222–229CrossRefPubMed
6.
go back to reference Doi Y, Minami T, Nishizawa M, Mabuchi T, Mori H, Ito S (2002) Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation. Neuroreport 13:93–96CrossRefPubMed Doi Y, Minami T, Nishizawa M, Mabuchi T, Mori H, Ito S (2002) Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation. Neuroreport 13:93–96CrossRefPubMed
7.
go back to reference Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539CrossRefPubMed Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539CrossRefPubMed
9.
go back to reference Feng CJ, Guo JB, Jiang HW et al (2008) Spatio-temporal localization of HIF-1alpha and COX-2 during irradiation-induced oral mucositis in a rat model system. Int J Radiat Biol 84:35–45CrossRefPubMed Feng CJ, Guo JB, Jiang HW et al (2008) Spatio-temporal localization of HIF-1alpha and COX-2 during irradiation-induced oral mucositis in a rat model system. Int J Radiat Biol 84:35–45CrossRefPubMed
10.
go back to reference Hong JH, Chiang CS, Tsao CY, Lin PY, McBride WH, Wu CJ (1999) Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 75:1421–1427CrossRefPubMed Hong JH, Chiang CS, Tsao CY, Lin PY, McBride WH, Wu CJ (1999) Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 75:1421–1427CrossRefPubMed
13.
go back to reference Lalla RV, Peterson DE (2006) Treatment of mucositis, including new medications. Cancer J 12:348–354CrossRefPubMed Lalla RV, Peterson DE (2006) Treatment of mucositis, including new medications. Cancer J 12:348–354CrossRefPubMed
14.
go back to reference Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin North Am 52:61–77CrossRefPubMed Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin North Am 52:61–77CrossRefPubMed
15.
go back to reference Lin CR, Amaya F, Barrett L et al (2006) Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319:1096–1103CrossRefPubMed Lin CR, Amaya F, Barrett L et al (2006) Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319:1096–1103CrossRefPubMed
16.
go back to reference Logan RM, Gibson RJ, Sonis ST, Keefe DM (2007) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43:395–401CrossRefPubMed Logan RM, Gibson RJ, Sonis ST, Keefe DM (2007) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43:395–401CrossRefPubMed
17.
go back to reference McGuire DB, Peterson DE, Muller S, Owen DC, Slemmons MF, Schubert MM (2002) The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest 20:893–903CrossRefPubMed McGuire DB, Peterson DE, Muller S, Owen DC, Slemmons MF, Schubert MM (2002) The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest 20:893–903CrossRefPubMed
19.
go back to reference Rapoport AP, Miller Watelet LF, Linder T et al (1999) Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 17:2446–2453PubMed Rapoport AP, Miller Watelet LF, Linder T et al (1999) Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 17:2446–2453PubMed
20.
go back to reference Rouzer CA, Marnett LJ (2008) Cyclooxygenases: structural and functional insights. J Lipid Res; 50: S29-34S. April 2009 Rouzer CA, Marnett LJ (2008) Cyclooxygenases: structural and functional insights. J Lipid Res; 50: S29-34S. April 2009
21.
go back to reference Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST (1998) The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82:2275–2281CrossRefPubMed Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST (1998) The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82:2275–2281CrossRefPubMed
22.
go back to reference Schubert MM, Sullivan KM, Morton TH et al (1984) Oral manifestations of chronic graft-v-host disease. Arch Intern Med 144:1591–1595CrossRefPubMed Schubert MM, Sullivan KM, Morton TH et al (1984) Oral manifestations of chronic graft-v-host disease. Arch Intern Med 144:1591–1595CrossRefPubMed
23.
go back to reference Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69:2469–2477CrossRefPubMed Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69:2469–2477CrossRefPubMed
24.
go back to reference Shankavaram UT, Lai WC, Netzel-Arnett S et al (2001) Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem 276:19027–19032CrossRefPubMed Shankavaram UT, Lai WC, Netzel-Arnett S et al (2001) Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem 276:19027–19032CrossRefPubMed
25.
go back to reference Sonis ST, Peterson RL, Edwards LJ et al (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373–381CrossRefPubMed Sonis ST, Peterson RL, Edwards LJ et al (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373–381CrossRefPubMed
26.
go back to reference Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMed Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMed
27.
go back to reference Sonis ST, O'Donnell KE, Popat R et al (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170–176CrossRefPubMed Sonis ST, O'Donnell KE, Popat R et al (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170–176CrossRefPubMed
28.
go back to reference Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598CrossRefPubMed Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598CrossRefPubMed
29.
go back to reference Tanner NS, Stamford IF, Bennett A (1981) Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. Br J Cancer 43:767–771PubMed Tanner NS, Stamford IF, Bennett A (1981) Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. Br J Cancer 43:767–771PubMed
30.
go back to reference Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice. Blood 83:2360–2367PubMed Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB (1994) Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice. Blood 83:2360–2367PubMed
31.
go back to reference Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D (2009) Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med; July 24 (Epub ahead of print) Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D (2009) Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med; July 24 (Epub ahead of print)
Metadata
Title
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study
Authors
Rajesh V. Lalla
Carol C. Pilbeam
Stephen J. Walsh
Stephen T. Sonis
Dorothy M. K. Keefe
Douglas E. Peterson
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0635-1

Other articles of this Issue 1/2010

Supportive Care in Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine